Dataset Information

Diagnostic and Prognostic Significance of Serum Neutrophil Gelatinase-Associated Lipocalin in Patients with Colorectal Cancer

ABSTRACT: Interventions: Colon cancer screening; Studies on tissue samples have shown that NGAL expression increases in CRCs and inflammatory bowel diseases. This study is planned to investigate the usability of serum NGAL level as a diagnostic and/or prognostic biomarker, in patients with colorectal cancer. NGAL level was determined through serum samples. Blood was taken from each patient only once, before polypectomy (for the polip group) or surgery (for the cancer group). Primary outcome(s): Diagnostic role of serum NGAL levels on colorectal cancer patients assessed with using Human NGAL/Lipocalin-2 ELISA kit. All colorectal cancer patients serum NGAL levels determined and compared with the other groups (benign colon polyps and healthy individual).[12 months after reciept of all blood samples.] Study Design: Purpose: Diagnosis; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Parallel

DISEASE(S): Colon Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2461212 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Purpose: There is a quest for novel non-invasive diagnostic markers for the detection of breast cancer. The goal of this study is to identify circulating microRNA signatures using a cohort of Asian Chinese breast cancer patients, and to compare microRNA profiles between tumour and serum samples. Experimental design: MicroRNAs from paired breast cancer tumours, normal tissue and serum samples derived from 32 patients were comprehensively profiled using microarrays (1300 microRNAs against tumour and normal tissues) or LNA RT-PCR panels (742 microRNAs against serum samples). Serum samples from healthy individuals (n=22) were also employed as normal controls. Significant serum microRNAs, identified by logistic regression, were validated in an independent set of serum samples from patients (n=82) and healthy controls (n=53). Results: The 20 most significant microRNAs differentially expressed in breast cancer tumours included miR-21, miR-10b, and miR-145, previously shown to be dysregulated in breast cancer. Interestingly, 16 of the 20 most significant microRNAs differentially expressed in serum samples were novel. MiR-1, miR-92a, miR-133a and miR-133b were identified as the most important diagnostic markers, and were successfully validated; receiver operating characteristic curves derived from combinations of these microRNAs exhibited areas under the curves of 0.944-0.946. Only seven microRNAs were overexpressed in both tumours and serum, suggesting that microRNAs may be released into the serum selectively. Conclusion: The clinical employment of microRNA signatures as a non-invasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers. Blood samples were collected in Becton Dickinson (Franklin Lakes, NJ) Vacutainer SST tubes. Serum was harvested by centrifugation at 2200g after allowing blood to clot for 30mins. 32 patient samples and 22 samples from healthy controls were obtained for profiling. Sera samples were stored at -80oC.

Dataset Information

Diagnostic and Prognostic Significance of Serum Neutrophil Gelatinase-Associated Lipocalin in Patients with Colorectal Cancer

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets